Viral evolutionary changes during tenofovir treatment in a chronic hepatitis B patient with sequential nucleos(t)ide therapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Hyun Woong | - |
dc.contributor.author | Chang, Hye Young | - |
dc.contributor.author | Yang, Suh Yoon | - |
dc.contributor.author | Kim, Hyung Joon | - |
dc.date.available | 2019-03-08T21:40:52Z | - |
dc.date.issued | 2014-07 | - |
dc.identifier.issn | 1386-6532 | - |
dc.identifier.issn | 1873-5967 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/12084 | - |
dc.description.abstract | A 54-year-old man diagnosed with HBeAg-positive chronic hepatitis B (CHB) was treated with entecavir (ETV) 1 mg/day following an initial unsuccessful lamivudine (LAM) treatment (rtL180M, rtM204V/I). Subsequently, virological breakthrough with ETV mutation (rtT184A/L) developed. The LAM and adefovir combination therapy was followed by virological breakthrough. The therapy had been switched to TDF monotherapy. However, this patient experienced virological breakthrough under TDF with a HBV strain bearing rtL80M, rtL180M, rtM204V/I, rtA200V, rtF221Y, rt5223A, rtT184A/L, rtR153Q, and rtV191I combined mutations without rtA194T mutation. TDF resistance may emerge due to multi-site polymerase mutations rather than single-site polymerase mutation. (C) 2014 Elsevier B.V. All rights reserved. | - |
dc.format.extent | 4 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | ELSEVIER SCIENCE BV | - |
dc.title | Viral evolutionary changes during tenofovir treatment in a chronic hepatitis B patient with sequential nucleos(t)ide therapy | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.jcv.2014.03.018 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL VIROLOGY, v.60, no.3, pp 313 - 316 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000339287200020 | - |
dc.identifier.scopusid | 2-s2.0-84902084849 | - |
dc.citation.endPage | 316 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 313 | - |
dc.citation.title | JOURNAL OF CLINICAL VIROLOGY | - |
dc.citation.volume | 60 | - |
dc.type.docType | Article | - |
dc.publisher.location | 네델란드 | - |
dc.subject.keywordAuthor | Tenofovir | - |
dc.subject.keywordAuthor | Chronic hepatitis B | - |
dc.subject.keywordAuthor | Resistance | - |
dc.subject.keywordAuthor | Mutation | - |
dc.subject.keywordPlus | VIRUS | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.subject.keywordPlus | SELECTION | - |
dc.subject.keywordPlus | FAILURE | - |
dc.relation.journalResearchArea | Virology | - |
dc.relation.journalWebOfScienceCategory | Virology | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.